DOTCHIN & ASSOCIATES, LLC for EMERGENT BIOSOLUTIONS
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
- H.R. 4341; S. 987 - CARA 3. - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366 S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Budget/Appropriations BUD
State Opioid Response Grants funding Substance Abuse and Mental Health Block Grant funding H.R. 2379 The State Opioid Response Grant Authorization Act of 2021 Appropriations funding for Fiscal Year 2022 - Further Extending Government Funding Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Defense DEF
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Health Issues HCR
S.4231 - Preparing for the Next Pandemic Act HR 3263 Outreach - DHS Medical Countermeasures Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.